MAIA Biotechnology, Inc. (NYSE American: MAIA) reported updated interim efficacy data from Part C of its Phase 2 THIO-101 expansion trial. The trial evaluates ateganosine, a novel telomere-targeting agent, as a third-line treatment for advanced non-small cell lung cancer (NSCLC).
The data, as of October 1, 2026, shows a disease control rate (DCR) of 88% in the efficacy evaluable population. This figure represents 38 patients out of 43 who achieved stable disease or better following treatment initiation. The company notes that this DCR is significantly higher than the 25% to 35% typically reported for standard third-line chemotherapy regimens.
THIO-101 is a multicenter, open-label trial designed to test the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo) will enhance and prolong immune response in patients who have progressed after prior immune checkpoint inhibitor therapy and chemotherapy. Patients receive ateganosine 180mg followed by cemiplimab in 21-day cycles.
MAIA has completed enrollment in Part C of the Phase 2 trial. The study enrolled patients in Hungary, Poland, Turkey, Georgia, Romania, Taiwan, and the United States. The company stated that the efficacy results from Part C are consistent with those observed in Parts A and B of the study.
Concurrently, an ongoing pivotal Phase 3 clinical trial of third-line ateganosine treatment, THIO-104, is advancing toward regulatory milestones, including a 2027 interim survival analysis. MAIA also stated that further data from THIO-101 Part C may support an accelerated approval filing with the FDA.